Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention

Current HIV Research

Volumn 11, Issue 6, 2013, Pages 473-480

  Bailey, Theodore C ^a   Sugarman, Jeremy ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Ethics; HIV; Justice; Pre exposure prophylaxis; Prevention; Treatment as prevention; Vaccine research

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; GENDER; HEALTH CARE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; MENTAL DISEASE; NATIONAL HEALTH ORGANIZATION; POVERTY; PRISON; PUBLIC HEALTH; RACISM; RISK REDUCTION; SOCIAL DISCRIMINATION; SOCIAL JUSTICE; UNEMPLOYMENT; VIOLENCE;

AIDS VACCINES; ANTI-HIV AGENTS; ETHICS, MEDICAL; HEALTH CARE RATIONING; HEALTH PRIORITIES; HIV INFECTIONS; HUMANS; SOCIAL JUSTICE;

EID: 84894094625     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x113116660054     Document Type: Article

References (109)

1. UNAIDS. Global HIV/AIDS response: epidemic update and health sector progress towards universal access, progress report 2011[document on the internet]. 2011 [cited 2013 Apr 16]. Available from: http://www.unaids.org/en/media/unaids/contentass ets/documents/unaidspublication/2011/20111130_ua_report_en.pdf
2. UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 2012[document on the internet]. 2012 [cited 2013 Apr 16]. Available from: http://www.unaids.org/en/media/unaids/conte ntassets/documents/epidemiology/2012/gr2012/20121120_UNAID S_Global_Report_2012_en.pdf
3. Santa-Ana-Tellez Y, de Maria LM, Galárraga O. Costs of interventions for AIDS orphans and vulnerable children. Trop Med Intl Health 2011; 16(11): 1417-26.
4. Abdool-Karim Q, Abdool-Karim SS, Frohlich JA, et al. Effective-ness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(59-96): 1168-74.
5. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemopro-phylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-99.
6. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367(5): 399-410.
7. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367(5): 423-34.
8. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
9. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381(9883): 2083-90.
10. WHO. Antiretroviral treatment as prevention (TasP) of HIV and TB: 2012 update [document on the internet]. Geneva: WHO; 2012 [cited 2013 Apr 16]. Available from: http://whqlibdoc.who.int/hq/ 2012/WHO_HIV_2012.12_eng.pdf.
11. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011; 15(Suppl 1): S72-9.
12. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS 2010; 24(Suppl 4): S70-80.
13. Cohen J. Shots in the dark: the wayward search for an AIDS vaccine. New York: W.W. Norton & Company; 2001.
14. Miedema F. A brief history of HIV vaccine research: stepping back to the drawing board? AIDS 2008; 22(14): 1699-703.
15. st ed. Bloomington and Indianapolis (IN): Indiana University Press; 1995.
16. Spearman P. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res 2003; 1(1): 101-20.
17. Munier CM, Anderson CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011; 71(4): 387-414.
18. HIV Vaccines and Microbicides Resource Tracking Working Group. Investing to end the AIDS epidemic: a new era for HIV prevention research & development [document on the internet]. 2012 [cited 2013 Apr 16]. Available from: http://www.hivresourcetracking.org/sites/default/files/July%202012%20Investing%20to%20End%20the%20AIDS%20Epidemic-%20A%20New%20Era%20for%20HIV%20Prevention%20Research%20&%20Development.pdf.
19. Cohen J. More woes for struggling HIV vaccine field. Science 2013; 340(6133): 667.
20. Bansal GP, Malaspina A, Flores J. Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010; 12(1): 39-46.
21. Kawalekar OU, Shedlock DJ, Weiner DB. Current strategies and limitations of HIV vaccines. Curr Opin Investig Drugs 2010; 11(2): 192-202.
22. Willyard C. Tiny steps towards an HIV vaccine. Nature 2010; 466(7304): S8.
23. Bradac J, Dieffenbach CW. HIV vaccine development: lessons from the past, informing the future. IDrugs 2009; 12(2): 435-9.
24. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321(5888): 530-2.
25. Buchbinder SB, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-I vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
26. NIH. NIH discontinues immunizations in HIV vaccine study [document on the internet]. Bethesda (MD): NIH; 2013 Apr 25[cited 2013 Apr 25]. Available from: http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx.
27. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
28. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366(14): 1275-86.
29. J. Unrevealed analysis weakens claim of AIDS vaccine "success." ScienceInsider [document on the internet] Science; 2009 Oct 5 [cited 2013 Apr 18]. Available from: http://news.sciencemag.org/scienceinsider/2009/10/unrevealed-anal.html.
30. Haynes BF, Liao HX, Tomaras GD. Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS 2010; 5(5): 362-7.
31. Baden LR, Dolin R. The road to an effective HIV vaccine. N Engl J Med 2012; 366(14): 1343-4.
32. Fauci AS, Folkers GK. Investing to meet the scientific challenges of HIV/AIDS. Health Aff 2009; 28(6): 1629-41.
33. Burton DR, Desrosiers RC, Doms RW, et al. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303(5656): 316.
34. McNeil JG, Johnston MI, Birx DL, Tramont EC. HIV vaccine trial justified. Science 2004; 303 (5660): 961.
35. Sternberg S. Biggest-ever AIDS vaccine trial draws stinging criticism. USA Today [newspaper online]. 2004 Jan 20 [cited 2013 Apr 18]: 7D. Available from: http://usatoday30.usatoday.com/news/health/2004-01-21-aids-vaccine_x.htm.
36. Grady, C. Ethics of vaccine research. Nat Immunol 2004; 5(5): 465-8.
37. Macklin R, Cowan E. Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Health Aff 2012; 31(7): 1537-44.
38. Brock DW, Wikler D. Ethical challenges in long-term funding for HIV/AIDS. Health Aff 2009; 28(6): 1666-76.
39. Singh JA. Antiretroviral resource allocation for HIV prevention. AIDS 2013; 27(6): 863-5.
40. Jay JS, Gostin LO. Ethical challenges of preexposure prophylaxis for HIV. JAMA 2012; 308(9): 867-8.
41. Gostin LO, Kim SC. Ethical allocation of preexposure HIV prophylaxis. JAMA 2012; 305(2): 191-2.
42. Rennie S. Ethical use of antiretroviral resources for HIV prevention in resource poor settings. Dev World Bioeth 2013; 13(2): 79-86.
43. Haire B, Kaldor JM. Ethics of ARV based prevention: treatment-as-prevention and PrEP. Dev World Bioeth 2013; 13(2): 63-9.
44. Faust HS, Menzel PT, editors. Prevention vs treatment: what's the right balance. New York: Oxford University Press; 2011.
45. Nichols EK. Expanding access to investigational therapies for HIV infection and AIDS. Washington D.C.: National Academy Press; 1991.
46. Amorosa V, Tebas P. Is it time to rethink expanded-access programs for HIV infection? J Infect Dis 2007; 197(7): 974-7.
47. th ed. New York: Oxford University Press; 2001.
48. Gostin LO, Powers M. What does social justice require for the public's health? public health ethics and policy imperatives. Health Aff 2006; 25(4): 1053-60.
49. Daniels N. Just health. New York: Cambridge University Press; 2008.
50. Ruger, JP. Health and social justice. New York: Oxford University Press; 2010.
51. Venkatapuram V. Health justice. Cambridge: Polity Press; 2011.
52. Powers M, Faden R. Social justice: the moral foundations of public health and health policy. New York: Oxford University Press; 2006.
53. Wolff J, de-Shalit A. Disadvantage. New York: Oxford University Press; 2007.
54. de Guzman A. Reducing social vulnerability to HIV/AIDS: models of care and their impact in resource-poor settings. AIDS Care 2001; 13(5): 663-75.
55. Blankenship KM, Bray SJ, Merson MH. Structural interventions in public health. AIDS 2000; 14(Suppl 1): S11-21.
56. Auerbach JD, Parkhurst JO, Cáceres CF. Addressing social drivers of HIV/AIDS for the long-term response: conceptual and methodological considerations. Glob Public Health 2011; 6(Suppl 3): S293-309.
57. Parker RG, Easton D, Klein CH. Structural barriers and facilitators in HIV prevention: a review of international research. AIDS 2000; 14 (Suppl 1): S22-32.
58. Gillespie S, Greener R, Whiteside A, Whitworth J. Investigating the empirical support for understanding vulnerability and the association between poverty, HIV infection, and AIDS impact. AIDS 2007; 21 (Suppl 7): S1-4.
59. Bishop-Sambrook C. HIV/AIDS susceptibility and vulnerability pathway: a tool for identifying indicators, role models, and innovations. In: Proceedings of Technical Consultation on Measuring Vulnerability in the Light of the HIV/AIDS Pandemic; 2003 Sept 9-11; Johannesburg. Rome:FAO; 2003 [cited 2013 Apr 16]. Available from: http://ftp.fao.org/SD/SDW/SDWP/HIV_AID S_pathway_14oct.pdf.
60. Tarantola D. Reducing HIV/AIDS risk, impact, and vulnerability. Bull World Health Organ 2000; 78(2): 236-7.
61. Mann J, Tarantola D. Responding to HIV/AIDS: a historical perspective. Health Hum Rights 1998; 2(4): 5-8.
62. Farmer P. Infections and inequalities: the modern plagues. Berkeley (CA): University of California Press; 1999.
63. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med 2005; 61(5): 1026-44.
64. Wodak A. Health, HIV infection, human rights, and injecting drug use. Health Hum Rights 1998; 2(4): 24-41.
65. Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and needs. J Acquir Immune Defic Syndr 2010; 55(Suppl 1): S56-62.
66. Hammett TM, Kling R, Johnston P, et al. Patterns of HIV prevalence and HIV risk behaviors among drug users prior to and 24 months following implementation of cross-border HIV prevention interventions in northern Vietnam and southern China. AIDS Educ Prev 2006; 18(2): 97-115.
67. Bao YP, Liu ZM. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS 2009; 20(6): 399-405.
68. Altman D. HIV, homophobia, and Human Rights. Health Hum Rights 1998; 2(4): 15-23.
69. van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009; 4(4): 300-7.
70. Beyrer C. Burma and Cambodia: human rights, social disruption, and the spread of HIV/AIDS. Health Hum Rights 1998; 2(4): 84-97.
71. Silverman JG, Raj A, Cheng DM. Sex trafficking and initiation-related violence, alcohol use, and HIV risk among HIV-infected sex workers in Mumbai, India. J Infect Dis 2011; 204(suppl 5): S1229-34.
72. Vuylsteke B, Semde G, Sika L, et al. High prevalence of HIV and sexually transmitted infections among male sex workers in Abidjan, Cote d'Ivoire: need for services tailored to their needs. Sex Transm Infect 2012; 88(4): 288-93.
73. Hodder SL, Justman J, Haley DF. Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr 2010; 55(Suppl 2): S69-73.
74. Wolde-Yohannes S. Persisting failure to protect populations at risk from HIV transmission: African American women in the United States (US). J Public Health Policy 2012; 33(3): 325-36.
75. Jackson H. Societal determinants of women's vulnerability to HIV in southern Africa. Health Hum Rights 1998; 2(4): 9-14.
76. Heise LL, Watts C, Foss A, et al. Apples and oranges? Interpreting success in HIV prevention trials. Contraception; 83(1): 10-5.
77. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199(1): 14-9.
78. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kismu, Kenya: a randomised controlled trial. Lancet 2007; 369(9562): 643-56.
79. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai Uganda: a randomized trial. Lancet 2007; 369(9562): 657-66.
80. Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV infected men and its effects on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374(9685): 229-37.
81. Byakika-Tusiime J. Circumcision and HIV infection: assessment of causality. AIDS Behav 2008; 12(6): 835-41.
82. Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9(11): 669-77.
83. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008; 300(14): 1674-84.
84. Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010; 24(11): 1749-56.
85. Millett GA, Crowley JS, Koh H, et al. A way forward: the National HIV/AIDS Strategy and reducing HIV incidence in the United States. J Aquir Immune Defic Syndr 2010; 55(Suppl 2): S144-7.
86. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011; 154(11): 766-71.
87. Needham CA, Canning R. Global disease eradication: the race for the last child. Washington D.C.: ASM Press; 2003.
88. Faden R, Kass N. HIV research, ethics, and the developing world. Am J Public Health 1998; 88(4): 548-50.
89. London L, Kagee A, Moodley K, Swartz L. Ethics, human rights and HIV vaccine trials in low income settings. J Med Ethics 2012; 38(5): 286-93.
90. Levine RJ. Ethical issues in international vaccine research and development. Yale J Biol Med 2005; 78(5): 231-7.
91. Macklin R. Double standards in medical research in developing countries. Cambridge: Cambridge University Press; 2004.
92. Macklin R. Standard of care: an evolution in ethical thinking. Lancet 2008; 372(9635): 284-5.
93. Richardson HS, Belsky L. The ancillary-care responsibilities of medical researchers: an ethical framework for thinking about the clinical care that researchers owe their subjects. Hastings Cent Rep 2004: 34(1): 25-33.
94. Hyder AA, Merritt MW. Ancillary care for public health research in developing countries. JAMA 2009; 302(4): 429-31.
95. Macklin R. Intertwining biomedical research and public health in HIV microbicide research. Public Health Ethics 2010; 3(3): 199-209.
96. Haire B, Kaldor J, Jordens CFC. How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention. Am J Bioeth 2012; 12(6): 21-30.
97. Haire B, Folayan MO, Hankins C, et al. Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP. Dev World Bioeth 2013; 13(2): 87-94.
98. HIV Prevention Trials Network. Ethics guidance for research [document on the internet]. Chapel Hill (NC): HPTN; 2009 [updated 2009 Jun 10; cited 2013 Apr 18]. Available from: http://www.hptn.org/web%20documents/EWG/HPTNEthicsGuidan ceV10Jun2009.pdf.
99. World Medical Association. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects [document on the internet]. Seoul: WMA; 2008 [cited 2013 Apr 18]. Available from: http://www. wma.net/en/30publications/10policies/b3/17c.pdf.
100. UNAIDS. Ethical considerations in biomedical HIV prevention trials [document on the internet]. Geneva: UNAIDS; 2007 [updated 2012; cited 2013 Apr 18]. Available from: http://www.unaids.org/ en/media/unaids/contentassets/documents/unaidspublication/2012/j c1399_ethical_considerations_en.pdf.
101. Rennie S, Sugarman J. Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach. J Med Ethics 2010; 36(12): 810-5.
102. CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011; 60(3): 65-8.
103. CDC. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR 2012; 61(31): 586-9.
104. WHO. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscodant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects [document on the internet]. Geneva: WHO; 2012 [cited 2013 Apr 18]. Available from: http://apps.who.int/iris/bitstream/10665/75188/1/9789241503884_e ng.pdf.
105. van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367(5): 411-22.
106. Marrazzo J, Ramjee G, Nair G, et al. Pre--exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). In: Proceedings of 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta. Alexandria (VA): CROI LLC; 2013 [cited 2013 Apr 18]. Available from: http://www.retrocon ference.org/2013b/Abstracts/47951.htm.
107. Grant R, Guanira J, Buchbinder S, et al. No excess in HIV incidence after stopping oral Emtricitabine/Tenofovir pre-exposure prophylaxis: the iPrEx trial. In: Proceedings of 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta. Alexandria (VA): CROI LLC; 2013 [cited 2013 Apr 18]. Available from: http://www.retroconference.org/2013b/Abstracts/46875.htm.
108. Microbicide Trials Network. Daily HIV prevention didn't work for African women in the VOICE study [document on the internet]. MTN; 2013 Mar 4 [cited 2013 Apr 18]. Available from: http://www.mtnstopshiv.org/node/4877.
109. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach [document on the internet]. Geneva: WHO; 2013 [cited 2013 Jul 3]. Available from: http://apps.who.int/iri s/bitstream/10665/85321/1/9789241505727_eng.pdf